Owing to increasing resistance and the limited arsenal of new antibiotics, especially against
Gram-negative pathogens, carefully designed antibiotic regimens are obligatory for febrile …

Objective To identify all interventions that increase or reduce mortality in patients with acute
kidney injury (AKI) and to establish the agreement between stated beliefs and actual …

Thalidomide and bortezomib are extensively used to treat elderly myeloma patients. In these
patients, treatment-related side effects are frequent and full drug doses difficult to tolerate …

Two-thirds of patients with multiple myeloma are aged 65years or more and the prevalence
of multiple myeloma in elderly patients is expected to rise in the next future. Patients older …

The role of thalidomide, bortezomib and lenalidomide in multiple myeloma patients
presenting with renal impairment was evaluated in 133 consecutive newly diagnosed …

This phase 2 study assessed the safety, pharmacokinetics, pharmacodynamics and efficacy
of carfilzomib, a selective proteasome inhibitor, in patients with multiple myeloma and …

Multiple myeloma is a rare, largely incurable malignant disease of plasma cells. Patients
usually present with hypercalcemia, renal insufficiency, anemia and/or lytic bony lesions …

Background. Treatment of multiple myeloma has dramatically improved with the introduction
of bortezomib (BOR), thalidomide (THAL), and lenalidomide (LEN). Studies assessing …

Background Biomarker identification is becoming increasingly important for the development
of personalized or stratified therapies. Metabolomics yields biomarkers indicative of …

A 71-year-old woman presented with extreme low back pain. Her lumbar spine radiographs
revealed a pathological fracture of L4. The hematology profile was normal (hemoglobin …